From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences —highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.
You can read the full article here:

From vendor to vanguard: Reimagining India’s role in global life sciences
Krishna Kanumuri
The pharmaceutical industry is undergoing a silent transformation—less headline-grabbing than AI or quantum computing, but just as profound. Behind every breakthrough drug lies a complex ecosystem of scientific ingenuity, operational discipline, and regulatory precision. At the heart of this ecosystem sits a sector long overlooked: CRDMOs.
For decades, Indian CRDMOs have been seen as efficient vendors—essential but interchangeable. That era is ending.
The future demands more. It calls for companies that can operate with the speed of a start-up and the quality of a multinational. That means rethinking what it means to lead, to innovate, and above all, to build. As someone who has spent a career in life sciences, I believe we are no longer just manufacturing molecules—we are building trust, capability, and a global reputation.

Leading at the edge
Leadership in our industry is often equated with size. I disagree. True leadership comes from how we respond to complexity. Today, complexity is everywhere: scientific, geopolitical, environmental. The companies that thrive will be those that lean into this complexity with agility, ethics, and ambition.
In our case, it has meant rewriting how we define performance. Not just on-time delivery, but how we solve scientific challenges. Not just compliance, but proactive quality. Not just sustainability as a box to tick, but a value embedded in every process. It also means being transparent when we fall short—and relentless in how we improve.

Innovation is a system, not a lab
We often glorify the eureka moment. But innovation isn’t just what happens in a lab—it’s the system that allows it to happen again and again.
At Sai Life Sciences, we’ve had to build this system brick by brick. It meant digitizing our labs not because it’s trendy, but because it helps a chemist test 100 hypotheses in the time it once took to test 10. It meant moving beyond service projects and co-designing development strategies with our clients—because we’re no longer just executors, we’re co-creators.
Innovation today isn’t about having the best tool—it’s about having the best process to unleash the best people.

Sustainability: The responsibility of scale
There is a saying in engineering: “What you design, you are responsible for.” The same holds true for the systems we scale.
As we grow, so does our responsibility—to our environment, to our communities, and to the generations of scientists we are shaping. Sustainable practices aren’t a trade-off with growth. They are growth.
We are investing in zero-liquid-discharge facilities not because regulations require it, but because the next generation of talent won’t work for a company that doesn’t take the planet seriously. We are reengineering solvent recovery systems, eliminating waste streams, and pushing suppliers to do the same. Because leadership means going first.

The mindset shift: From scarcity to abundance
Entrepreneurship is not just about launching a company—it’s about how you think. And in India, we’ve been trained in a mindset of scarcity: cut costs, reduce risk, stay behind.
That’s changing. The best scientists in India don’t want to be part of a back-end operation. They want to build something meaningful, something global. Our job as leaders is to create space for them to do that—through risk-sharing, global exposure, and a culture that prizes initiative over hierarchy.
We don’t need to copy Silicon Valley. We can build our own model of entrepreneurship—one rooted in science, long-term thinking, and quiet confidence.

The opportunity to redefine
India’s CRDMO sector has reached a pivotal point—not just to grow, but to redefine what we are. We can continue being the reliable, low-cost option. Or we can become something far more powerful: the partner of choice for the world’s most ambitious science.
At Sai Life Sciences, we choose the latter. Not because it’s easy. But because the future deserves better—and we’re ready to build it.